CAI CORP (00080) net asset value per share at the end of August was approximately HK$0.16.
CAI Corp (00080) announced that as of August 31, 2026, the unaudited net asset value per share of CAI Corp (the Company) and its subsidiaries was approximately HK$0.16.
CAI CORP (00080) announced that as of August 31, 2026, the unaudited net asset value per share of CAI CORP (the Company) and its subsidiaries was approximately HK$0.16.
Related Articles
Citi: Raises PRADA (01913) target price to HK$41.5, maintains "Neutral" rating.
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25012 Injection Receives Clinical Trial Approval Notice
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Heparin Sodium Injection obtains Moldova drug registration certificate.
Citi: Raises PRADA (01913) target price to HK$41.5, maintains "Neutral" rating.
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-25012 Injection Receives Clinical Trial Approval Notice
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Heparin Sodium Injection obtains Moldova drug registration certificate.
RECOMMEND
